These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35490155)

  • 1. Beyond BCL-2 Inhibition in Acute Myloid Leukemia: Other Approaches to Leverage the Apoptotic Pathway.
    Maiti A; Carter BZ; Andreeff M; Konopleva MY
    Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):652-658. PubMed ID: 35490155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Action of MCL-1 Inhibitor with BCL-2/BCL-XL or MAPK Pathway Inhibitors Enhances Acute Myeloid Leukemia Cell Apoptosis and Differentiation.
    Opydo M; Mlyczyńska A; Mlyczyńska E; Rak A; Kolaczkowska E
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.
    Wergeland L; Sjøholt G; Haaland I; Hovland R; Bruserud Ø; Gjertsen BT
    Mol Cancer; 2007 May; 6():33. PubMed ID: 17498302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia.
    Ochiiwa H; Ailiken G; Yokoyama M; Yamagata K; Nagano H; Yoshimura C; Muraoka H; Ishida K; Haruma T; Nakayama A; Hashimoto N; Murata K; Nishimura M; Kawashima Y; Ohara O; Ohkubo S; Tanaka T
    Oncogene; 2021 Feb; 40(7):1217-1230. PubMed ID: 33420360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
    Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
    Carter BZ; Mak PY; Tao W; Ayoub E; Ostermann LB; Huang X; Loghavi S; Boettcher S; Nishida Y; Ruvolo V; Hughes PE; Morrow PK; Haferlach T; Kornblau S; Muftuoglu M; Andreeff M
    Blood Cancer J; 2023 Apr; 13(1):57. PubMed ID: 37088806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells.
    Carter BZ; Mak PY; Muftuoglu M; Tao W; Ke B; Pei J; Bedoy AD; Ostermann LB; Nishida Y; Isgandarova S; Sobieski M; Nguyen N; Powell RT; Martinez-Moczygemba M; Stephan C; Basyal M; Pemmaraju N; Boettcher S; Ebert BL; Shpall EJ; Wallner B; Morgan RA; Karras GI; Moll UM; Andreeff M
    Blood; 2023 Sep; 142(12):1056-1070. PubMed ID: 37339579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
    Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M
    Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
    Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
    Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
    Choi JH; Bogenberger JM; Tibes R
    Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.
    Lewis AC; Pope VS; Tea MN; Li M; Nwosu GO; Nguyen TM; Wallington-Beddoe CT; Moretti PAB; Anderson D; Creek DJ; Costabile M; Ali SR; Thompson-Peach CAL; Dredge BK; Bert AG; Goodall GJ; Ekert PG; Brown AL; D'Andrea R; Robinson N; Pitman MR; Thomas D; Ross DM; Gliddon BL; Powell JA; Pitson SM
    Blood; 2022 Jun; 139(26):3737-3751. PubMed ID: 35443029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L; Dittmann J; Vogler M; Fulda S
    Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P; Zerbinati C; di Iasio MG; Melloni E; Tiribelli M; Grill V; Zauli G
    Curr Drug Metab; 2007 May; 8(4):395-403. PubMed ID: 17504227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells.
    Sarif Z; Tolksdorf B; Fechner H; Eberle J
    Mol Carcinog; 2020 Nov; 59(11):1256-1268. PubMed ID: 32885857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway.
    Shi YF; Liu L; He LL; Ye J; Lin ZJ; Yuan DL; Deng MM; Fang ZH; Carter BZ; Xu B
    Cell Death Dis; 2020 Jul; 11(7):555. PubMed ID: 32699295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.